What factors predict a favorable outcome in young children with disseminated neuroblastoma?
Brian H Kushner* and Nai-Kong V Cheung
Correspondence *Department of Pediatrics, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Email kushnerb@mskcc.org
This article has no abstract so we have provided the first paragraph of the full text.
Fifty percent of patients with neuroblastoma have metastatic (stage 4) disease. Infants whose neuroblastoma lacks amplification of the MYCN proto-oncogene do well with low-dose chemotherapy, but older patients have a poor prognosis even with intensive chemotherapy, regardless of MYCN status. Now, however, the long-accepted 1-year age cutoff for predicting prognosis has been rendered obsolete. This retrospective study published by the Pediatric Oncology Group (POG), and similar analyses from the Children's Cancer Group (CCG),1, 2 and the Cooperative German Group2 reveal that patients with stage 4 non-MYCN-NB who are aged 12–18 months fare almost as well as younger, and far better than older, patients.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.